Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 183 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Women Contraception Clear all

Conditions: Obesity
Interventions: PF-07081532, Semaglutide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Contraception
Interventions: Relugolix Combination Therapy; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 109
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more

Conditions: Contraception
Interventions: FemBloc® Permanent Contraceptive System; Device
Lead sponsor: Femasys Inc.; Industry
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 5
States / cities: Stamford, Connecticut • Miami, Florida • New York, New York + 2 more

Conditions: Contraception, Contraception Behavior, Prepregnancy Health, Reproductive Health
Interventions: MyPath Web-Based Informational and Decision Support Tool; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 465 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 12
States / cities: San Diego, California • Aurora, Colorado • Orlando, Florida + 9 more

Conditions: Contraception
Interventions: Gestodene/EE (FC Patch Low, BAY86-5016), Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 346 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 28
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 25 more

Conditions: Rheumatic Diseases, Physician-Patient Relations, Contraception
Interventions: MyVoice:Rheum, Pamphlet; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Change in Bone Mineral Density, Bone Loss
Interventions: drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet; Drug
Lead sponsor: Insud Pharma; Industry
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 1,536 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 27
States / cities: Phoenix, Arizona • Aurora, Colorado • Boynton Beach, Florida + 17 more

Conditions: Sterility, Female, Contraception, Contraceptive Device; Complications
Interventions: Essure, Laparoscopic sterilization, Intrauterine Device (IUD); Device · Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 89,203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Contraception
Interventions: Ulipristal Acetate, Levonorgestrel; Drug
Lead sponsor: Kimberly Myer; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 532 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 18
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 14 more

Conditions: Contraceptive Usage, Coagulation
Interventions: DHEA Oral Capsule, Placebo Oral Capsule; Dietary Supplement · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Contraceptive Devices, Long-Acting Reversible Contraception, Analgesia, Adolescent Health, Gynecology
Interventions: Nitrous oxide gas for inhalation, Oxygen Gas for Inhalation; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 14 Years to 24 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Contraception, Obesity
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Birth Control
Interventions: WC then FC2, FC2 then WC; Device
Lead sponsor: CONRAD; Other
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Contraception
Interventions: Subcutaneous depot medroxyprogesterone acetate; Drug
Lead sponsor: Planned Parenthood Federation of America; Other
Eligibility: 15 Years to 44 Years · Female only
Enrollment: 401 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Morristown, New Jersey • Houston, Texas

Conditions: Overweight, Obesity
Interventions: NNC0662-0419, Oral contraceptive, Acetaminophen; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Contraception, Counseling
Interventions: Contraception Handout, Nutritional Handout; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Contraception
Interventions: Etonogestrel contraceptive implant; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Vitamin B6 Deficiency
Interventions: Vitamin B6, Infusion of labeled serine, methionine and leucine; Dietary Supplement · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: IUD, Healthy Female, Contraception, IUD Insertion Complication
Interventions: Ketorolac, Placebo; Drug
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 13 Years to 21 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Substance Use Disorders, Pregnancy Related, Contraception
Interventions: MyPath Intervention, Usual care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Neural Tube Defects, Contraception, Oral Contraceptives (OC)
Interventions: Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 385 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 9
States / cities: Anaheim, California • San Diego, California • Baltimore, Maryland + 6 more

Conditions: Dysmenorrhea, Heavy Menstrual Bleeding, Contraception
Interventions: Transabdominal Ultrasound; Diagnostic Test
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 12 Years to 22 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Pregnancy Prevention
Interventions: Levonorgestrel 1.5 milligram, Meloxicam 15 milligram, calcium carbonate 750 milligram; Drug · Other
Lead sponsor: InnovaGyn, Inc.; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Hemostasis, Oral Contraceptive
Interventions: 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive; Drug
Lead sponsor: Teva Women's Health; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 265 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more

Search by objective public record fields.

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception

Patient-Centered Reproductive Decision Support Tool for Women Veterans

US Cycle Control and Blood Pressure Study

MyVoice:Rheum Decision Aid for Women With Rheumatic Diseases

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization

Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills

Nitrous Oxide for Pain Management During IUD Insertion in Nulliparous Adolescent Women

The Effect of Body Mass Index on Etonogestrel Hormone Levels in Women Using the Single-rod Contraceptive Implant

Prostate Specific Antigen (PSA) and Acute Failure Modes Study of the PATH Woman's Condom and FC2 Female Condom

Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

Effect of Formal Contraception Handouts

Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study

Vitamin B6 Effects for Women Taking Birth Control Pills

Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement

Implementation of a Patient-centered, Reproductive Planning Decision Support Tool (MyPath) Among Women With Substance Use Disorder in the Immediate Postpartum Period

Efficacy and Safety Study for an Oral Contraceptive Containing Folate

Ultrasound Evaluation Versus Direct Measurement of Uterine Cavity Length

Phase II Study of Ovulation in Obese Women

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women